NSG/501 Week 4: Evaluating Pharmacological Interventions, sample paper

Alendronate, Zoledronic Acid or Denosumab? Evaluating Drug Therapy Against the Mechanism and the Assessment for a 68-Year-Old After a Wrist Fracture

[Student Name]

University of Phoenix

NSG/501: Pathophysiology, Assessment Variables and Pharmacology I

Week 4 Assignment

[Instructor Name]

[Date]

The patient and her circumstances are a composite written for a model paper.

In Week 3, I placed each osteoporosis treatment on a concept map at the step of the disease it acts on. This paper evaluates the main drug options for Mrs. D., the 68-year-old woman seen after a wrist fracture, by comparing how each works, what the evidence shows, how it is taken and what can go wrong, and then weighing the options against her assessment findings.

Treatment Is Indicated

Mrs. D. has osteoporosis by bone density, a fragility fracture after age 50 and a ten-year hip fracture probability of about 6%. Guidelines for postmenopausal women recommend drug treatment for women at high fracture risk, with bisphosphonates as first-line therapy for most and denosumab as an alternative (Eastell et al., 2019). Before any drug, her vitamin D insufficiency should be corrected and her calcium intake raised, since both support the drugs' effect and reduce the risk of low calcium during treatment.

Option 1: Oral Alendronate

Mechanism: alendronate is a bisphosphonate. It binds to hydroxyapatite on bone surfaces and is taken up by osteoclasts during resorption, where it disrupts their function and shortens their survival, reducing remodeling (Compston et al., 2019). On the Week 3 map, it acts on the remodeling imbalance.

Administration: 70 mg once weekly, taken first thing in the morning with a full glass of plain water, at least 30 minutes before food, drink or other medications, while staying upright for 30 minutes.

Risks and concerns: upper gastrointestinal irritation, including esophagitis, is the most common reason for stopping. Rare but serious effects of long-term bisphosphonate use include osteonecrosis of the jaw and atypical femoral fractures. Oral bisphosphonates are generally avoided when kidney function is severely reduced.

Fit for Mrs. D.: the strict dosing rules and gastrointestinal effects are a concern, because she has reflux treated daily with omeprazole. Poor adherence to oral bisphosphonates is common even without reflux, and a drug that is not taken does not prevent fractures.

Option 2: Intravenous Zoledronic Acid

Mechanism: zoledronic acid is a more potent bisphosphonate acting on the same step.

Evidence: in the HORIZON trial of postmenopausal women with osteoporosis, a 15-minute infusion once a year for three years reduced morphometric vertebral fractures by 70%, from 10.9% with placebo to 3.3%, and hip fractures by 41%, from 2.5% to 1.4% (Black et al., 2007).

Administration: 5 mg by intravenous infusion over at least 15 minutes once a year, with good hydration beforehand.

Risks: an acute-phase reaction of fever, muscle aches and flu-like symptoms is common after the first infusion and usually lasts one to three days; acetaminophen can reduce it. Kidney function must be checked before each dose, and the drug is not given when creatinine clearance is below 35 mL/min. Vitamin D must be adequate first, since the drug can lower calcium.

Fit for Mrs. D.: once-yearly infusion avoids her reflux and the dosing rules of oral therapy and makes adherence simple. Her kidney function is adequate. Her vitamin D must be repleted before the first dose.

Option 3: Denosumab

Mechanism: denosumab is a monoclonal antibody that binds RANKL, preventing it from activating osteoclasts, which acts directly on the pathway described in Week 1.

Evidence: in the FREEDOM trial, denosumab given every six months for three years reduced new vertebral fractures from 7.2% to 2.3%, a relative decrease of 68%, hip fractures from 1.2% to 0.7%, a relative decrease of 40%, and nonvertebral fractures by 20% compared with placebo (Cummings et al., 2009).

Administration: 60 mg by subcutaneous injection every six months.

Risks: hypocalcemia, especially with vitamin D deficiency or kidney disease, and the same rare jaw and femur risks. Denosumab's most important risk for nurses is what happens when it stops. When doses are missed, bone turnover markers rise above baseline within six months, bone density returns to baseline by twelve months, and some women develop multiple vertebral fractures (Cummings et al., 2018). Stopping denosumab therefore requires a planned switch to a bisphosphonate.

Fit for Mrs. D.: denosumab works well and does not depend on kidney function, but it commits her to injections every six months indefinitely or to a planned transition. For a patient who has never been treated, with normal kidneys, it is a reasonable second choice rather than a first.

Anabolic Therapy

Teriparatide, abaloparatide and romosozumab build new bone and are recommended first for women at very high risk, such as those with multiple vertebral fractures or a recent fracture with very low density (Eastell et al., 2019). Mrs. D.'s possible silent vertebral fractures, suggested by her height loss, should be checked with spine imaging. If imaging showed multiple vertebral fractures, she might move into the very high risk group and anabolic therapy would be considered first.

The Choice

For Mrs. D., yearly intravenous zoledronic acid is the best fit, provided her spine imaging does not place her in the very high risk group. It has strong evidence for both vertebral and hip fractures, avoids her reflux and the adherence problems of oral therapy and requires only one visit a year. Her vitamin D should be repleted first, her creatinine checked before each infusion and her dental health reviewed. Treatment would usually be reassessed after three to five years.

Weighing Adherence Against Potency

The choice between drugs is not only a question of which is most effective in trials. Trials measure what a drug does when patients take it, and in daily practice many do not. Oral bisphosphonates in particular are often stopped within the first year, because of the dosing rules, stomach symptoms or a belief that a drug with no noticeable effect is not needed. For Mrs. D., whose first education priority in Week 2 was understanding why she needs treatment at all, a regimen that requires one decision a year is more likely to protect her than a more demanding regimen with similar trial results. Denosumab requires two decisions a year and carries a penalty for missing one, and zoledronic acid carries no rebound when a dose is late. This reasoning also explains why the nurse's role at follow-up, confirming that the next infusion is booked, is as important as the prescription itself.

Nursing Monitoring

Before the infusion, the nurse confirms vitamin D repletion, creatinine and calcium, asks about planned dental work and ensures hydration. After the infusion, the nurse teaches her to expect possible flu-like symptoms and to use acetaminophen, and to report thigh or groin pain or jaw pain. At follow-up, the nurse confirms the next yearly infusion is scheduled, since missed doses are the most common reason treatment fails.

Conclusion

All three drugs act on the remodeling imbalance at the center of the disease, but they differ in how they are given and what can go wrong. Against Mrs. D.'s findings, especially her reflux and her need for simple adherence, yearly zoledronic acid is the best choice, with denosumab as a reasonable alternative. Week 5 will build the full plan of care around this choice.

References

Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T. F., Sellmeyer, D., ... Cummings, S. R. (2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine, 356(18), 1809-1822. https://doi.org/10.1056/NEJMoa067312

Compston, J. E., McClung, M. R., & Leslie, W. D. (2019). Osteoporosis. The Lancet, 393(10169), 364-376. https://doi.org/10.1016/S0140-6736(18)32112-3

Cummings, S. R., Ferrari, S., Eastell, R., Gilchrist, N., Jensen, J.-E. B., McClung, M., Roux, C., Törring, O., Valter, I., Wang, A. T., & Brown, J. P. (2018). Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. Journal of Bone and Mineral Research, 33(2), 190-198. https://doi.org/10.1002/jbmr.3337

Cummings, S. R., San Martin, J., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., Kutilek, S., Adami, S., Zanchetta, J., Libanati, C., Siddhanti, S., & Christiansen, C. (2009). Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England Journal of Medicine, 361(8), 756-765. https://doi.org/10.1056/NEJMoa0809493

Eastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019). Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 104(5), 1595-1622. https://doi.org/10.1210/jc.2019-00221